Washington, D.C. 20549



Form 8-K




Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): April 12, 2012



Sagent Pharmaceuticals, Inc.

(Exact name of registrant as specified in its charter)



Commission File Number: 1-35144


Delaware   98-0536317

(State or other jurisdiction

of incorporation)


(IRS Employer

Identification No.)

1901 N. Roselle Road, Suite 700, Schaumburg, Illinois 60195

(Address of principal executive offices, including zip code)

(847) 908-1600

(Registrant’s telephone number, including area code)

(Former name or former address, if changed since last report)



Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:


¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)


¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)


¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))


¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))




Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

On April 12, 2012, the Board of Directors (the “Board”) of Sagent Pharmaceuticals, Inc. (the “Company”) nominated its President and Chief Executive Officer, Jeffrey M. Yordon, to stand for election as a Class I director at its 2012 Annual Meeting of Stockholders, and on that same date, Mr. Yordon notified the Board that he will resign as a Class III director of the Company upon his election as a Class I director. The Company filed its definitive proxy statement in connection with the 2012 Annual Meeting of Stockholders with the SEC on April 13, 2012.


Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.


Date: April 16, 2012      


    Name:   Michael Logerfo

Executive Vice President, Chief Legal Officer and Corporate